Kidney disease and increased mortality risk in type 2 diabetes.

By M. Afkarian, Michael C. Sachs, B. Kestenbaum, I. Hirsch, K. Tuttle, Jonathan Himmelfarb, I. D. de Boer. Journal of the American Society of Nephrology, 2013

1,147 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. (2011, background): “[1] Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al.”
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “22,23 Consequently, the most common causes of death for people with diabetes and CKD are HF and atherosclerotic CVD (ASCVD), 24–26 and only ≈ 10% of patients with CKD even survive to reach kidney failure.”
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “29 As a result of the potent risk associations for CKM syndrome, prior continuous declines in CVD mortality rates achieved over 5 decades have recently begun to plateau, with increasing CVD mortality rates seen in some subpopulations.”
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022, background): “Moreover, CKD markedly amplifies risks of ASCVD, heart failure (HF), cardiovascular death, and all-cause mortality among people with diabetes.(7,8)”